BeiGene receives European Commission approval for Brukinsa (zanubrutinib) for the treatment of adults with chronic lymphocytic leukaemia

BeiGene

17 November 2022 - Brukinsa is the only Bruton’s tyrosine kinase inhibitor to achieve superiority over ibrutinib in relapsed/refractory chronic lymphocytic leukaemia.

BeiGene today announced that the European Commission has approved Brukinsa (zanubrutinib) for the treatment of adult patients with treatment naïve or relapsed/refractory chronic lymphocytic leukaemia.

Read BeiGene press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Europe